
Can AI Rescue Cancer Drugs That Clinical Trials Say Have Failed?
In this episode of Diagnosing Dx, David Filby is joined by Alexander Bagaev, Chief Product Officer at BostonGene. Alexander has spent more than a decade helping build BostonGene from an early-stage team into a global precision medicine company. In this conversation, we explore why oncology is moving beyond single biomarkers and how BostonGene has expanded from diagnostics into AI-powered treatment selection and clinical trial support. We also discuss the challenge of bringing more comprehensive diagnostics into routine use, the role of multimodal data in better decision-making, and how BostonGene is working with pharma to design smarter trials from the outset. This is a practical conversation about precision oncology, multimodal diagnostics, AI in drug development, and turning complex biology into clinically useful decisions.
Publisher
Diagnosing Dx
Published
July 15, 2026
Duration
36 min
Format
Podcast
Category
Issues · Science
Source
RSS feed
Host
Elevra Consulting
Diagnosing Dx
@diagnosingdx
#airescuecancer #clinicaltrials #failed #lifesciences
